STRS Ohio’s Travere Therapeutics TVTX Stock Holding History

STRS Ohio’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,600	Closed	-$114K	–	2433
2021 Q1	$114K	Hold	4,600	–	–	﹤0.01%	1918
2020 Q4	$125K	Buy	+4,600	New	+$107K	﹤0.01%	1849
2020 Q3	–	Sell	-4,600	Closed	-$93K	–	2280
2020 Q2	$93K	Hold	4,600	–	–	﹤0.01%	1807
2020 Q1	$67K	Hold	4,600	–	–	﹤0.01%	1746
2019 Q4	$65K	Sell	4,600 -30,100	-87%	-$384K	﹤0.01%	1852
2019 Q3	$402K	Hold	34,700	–	–	﹤0.01%	1407
2019 Q2	$697K	Buy	34,700 +2,400	+7%	+$47.4K	﹤0.01%	1016
2019 Q1	$730K	Hold	32,300	–	–	﹤0.01%	982
2018 Q4	$730K	Hold	32,300	–	–	﹤0.01%	936
2018 Q3	$927K	Sell	32,300 -2,600	-7%	-$74.3K	﹤0.01%	918
2018 Q2	$951K	Sell	34,900 -900	-3%	-$24K	﹤0.01%	924
2018 Q1	$800K	Sell	35,800 -3,300	-8%	-$78.6K	﹤0.01%	1009
2017 Q4	$823K	Buy	39,100 +2,600	+7%	+$59.4K	﹤0.01%	971
2017 Q3	$908K	Buy	+36,500	New	+$804K	﹤0.01%	919

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

STRS Ohio's TVTX Position: Q2 2021 in Review

STRS Ohio sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 4,600 shares — an estimated $114K sold.

STRS Ohio first reported a position in TVTX in Q3 2017 and held it in 14 quarters. The position peaked at $951K in Q2 2018. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

STRS Ohio reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
STRS Ohio sold 4,600 Travere Therapeutics shares in Q2 2021, an estimated $114K.
STRS Ohio first reported a position in Travere Therapeutics in Q3 2017 and held it in 14 quarters.
STRS Ohio's Travere Therapeutics position peaked at $951K in Q2 2018.
136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on STRS Ohio's 13F filing for Q2 2021, filed 26 Jul 2021.